SCHEMBL5056477

SCHEMBL5056477

CNc1ncc2cc(-c3cccc(NC(=O)Nc4cnc(C(C)(C)C)nc4N4CCOCC4)c3)c(=O)n(C)c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 6/20 0.45
FGFR1 P11362 5/20 0.45
PDGFRB P09619 2/20 0.45
PDGFRA P16234 2/20 0.45
SLC2A1 P11166 1/20 0.45
PKMYT1 Q99640 1/20 0.45
EGFR P00533 2/20 0.42
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
ABL1 P00519 3/20 0.40
PIK3CD O00329 1/20 0.40
BRD4 O60885 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CG P48736 1/20 0.40
MAPK14 Q16539 1/20 0.40
FGFR4 P22455 3/20 0.40
FGFR2 P21802 2/20 0.40
FGFR3 P22607 2/20 0.40
STK4 Q13043 1/20 0.38
STK3 Q13188 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5055210 0.89 BRAF (0.48) SRCFGFR1PDGFRBPDGFRASLC2A1
Hydrochloric Acid SCHEMBL5065369 0.88 BRAF (0.47) SRCFGFR1PDGFRBPDGFRASLC2A1
SCHEMBL4277858 0.85 SRC (0.47) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL5060340 0.83 SRC (0.43) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL5056532 0.83 RAF1 (0.47) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL5062562 0.83 FGFR1 (0.46) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL5054961 0.83 SRC (0.44) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL5054636 0.81 SRC (0.43) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL4420200 0.81 BRAF (0.49) SRCFGFR1PDGFRBPDGFRAEGFR
Hydrochloric Acid SCHEMBL4419083 0.81 BRAF (0.48) SRCFGFR1PDGFRBPDGFRAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 SRC 69/4885FGFR1 184/4885PDGFRB 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.